DelMar Pharmaceuticals Receives Approval from China's Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM

Biomarker-driven clinical trial will explore safety and efficacy of chemoradiation with VAL-083 as an alternative to standard-of-care temozolomide in MGMT-unmethylated GBM VANCOUVER, British Columbia…Read More »

DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

VANCOUVER, British Columbia and MENLO PARK, Calif., July 18, 2017 /PRNewswire/ — DelMar Pharmaceuticals (Nasdaq: DMPI) (“DelMar” and “the Company”), a biopharmaceutical company focused on the develop…Read More »

DelMar Pharmaceuticals Appoints Saiid Zarrabian to the Board of Directors and Names Dr. Erich Mohr as Chairman

Company Adopts Omnibus Equity Incentive Plan and Policy to Better Align with Shareholder Values and Facilitate Growth VANCOUVER, British Columbia and MENLO PARK, Calif., July 11, 2017 /PRNewswire/ — …Read More »

DelMar Pharmaceuticals Joins National Brain Tumor Society's Research Roundtable

VANCOUVER, British Columbia and MENLO PARK, Calif., June 29, 2017 /PRNewswire/ — DelMar Pharmaceuticals (Nasdaq: DMPI) (“DelMar” and the “Company”), a biopharmaceutical company focused on developing…Read More »

DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

VANCOUVER, British Columbia and MENLO PARK, Calif., June 22, 2017 /PRNewswire/ — DelMar Pharmaceuticals (Nasdaq: DMPI) (“DelMar” and “the Company”), a biopharmaceutical company focused on the develop…Read More »

Forward Looking Statements

Any statements contained in this blog that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.

This Blog is official and sanctioned by DelMar Pharmaceuticals, Inc.

Get DelMar Pharmaceuticals, Inc. Blog Post Alerts